Alkermes sells addiction and schizophrenia medicines.
Alkermes plc (ALKS) is expected to report earnings on Tuesday, October 27, 2026, after the close. Estimated release time 07:05 ET. Consensus EPS estimate is $-0.08.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-05-05 | FY2026 Q1 | $-0.57 | $-0.40 | +29.8% | $392.91M |
| 2026-02-25 | FY2025 Q4 | $0.43 | $0.34 | -20.9% | $384.55M |
| 2025-10-28 | FY2025 Q3 | $0.37 | $0.50 | +35.6% | $394.19M |
| 2025-07-29 | FY2025 Q2 | $0.41 | $0.53 | +29.3% | $390.66M |
| 2025-05-01 | FY2025 Q1 | $0.25 | $0.29 | +13.9% | $306.51M |
| 2025-02-12 | FY2024 Q4 | $0.81 | $0.90 | +11.1% | $429.99M |
| 2024-10-24 | FY2024 Q3 | $0.74 | $0.57 | -23.0% | $378.14M |
| 2024-07-24 | FY2024 Q2 | $0.70 | $0.54 | -22.9% | $399.13M |
ALKS has beaten consensus EPS in 5 of its last 8 reported quarters.
See ALKS on the live calendar →